Leukemia-associated fusion proteins: Multiple mechanisms of action to drive cell transformation

Research output: Contribution to journalArticle

Abstract

Leukemic cells are defined by two main biological features: arrest of differentiation at a specific stage compatible with continued proliferation, and enhanced resistance to stress. Recent work shows that the leukemia-associated fusion protein PML-RAR can mediate both biological effects targeting independent pathways, through a unifying mechanism. Differentiation block is achieved through transcriptional silencing of genes physiologically regulated by RAR, which are involved in hematopoietic differentiation. In contrast, enhanced resistance to stress is due to the capacity of the fusion protein to cause degradation of the tumor suppressor p53, thus explaining the puzzling observation that mutations of p53 are remarkably rare in acute myeloid leukemias (AMLs). Interestingly, this latter phenomenon depends on expression of wild-type PML, acting as a molecular bridge between p53 and the fusion protein. Strikingly, both effects require a unifying molecular mechanism: aberrant recruitment of histone deacetylases (HDACs). Therefore, the study of this form of leukemia appears also of interest for a better understanding of the action of HDAC inhibitors, potential antitumor drugs that are at the early stages of clinical studies.

Original languageEnglish
Pages (from-to)67-69
Number of pages3
JournalCell Cycle
Volume4
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Leukemia
Histone Deacetylases
Fusion reactions
Proteins
Gene Silencing
Acute Myeloid Leukemia
Antineoplastic Agents
Tumors
Genes
Degradation
Mutation
Neoplasms
Clinical Studies

Keywords

  • Apoptosis
  • Leukemia
  • Mouse model
  • Oncogenic fusion protein
  • p53

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

@article{a3f5ea1414e54192a139984682b44634,
title = "Leukemia-associated fusion proteins: Multiple mechanisms of action to drive cell transformation",
abstract = "Leukemic cells are defined by two main biological features: arrest of differentiation at a specific stage compatible with continued proliferation, and enhanced resistance to stress. Recent work shows that the leukemia-associated fusion protein PML-RAR can mediate both biological effects targeting independent pathways, through a unifying mechanism. Differentiation block is achieved through transcriptional silencing of genes physiologically regulated by RAR, which are involved in hematopoietic differentiation. In contrast, enhanced resistance to stress is due to the capacity of the fusion protein to cause degradation of the tumor suppressor p53, thus explaining the puzzling observation that mutations of p53 are remarkably rare in acute myeloid leukemias (AMLs). Interestingly, this latter phenomenon depends on expression of wild-type PML, acting as a molecular bridge between p53 and the fusion protein. Strikingly, both effects require a unifying molecular mechanism: aberrant recruitment of histone deacetylases (HDACs). Therefore, the study of this form of leukemia appears also of interest for a better understanding of the action of HDAC inhibitors, potential antitumor drugs that are at the early stages of clinical studies.",
keywords = "Apoptosis, Leukemia, Mouse model, Oncogenic fusion protein, p53",
author = "Alessandra Insinga and Pelicci, {Pier Giuseppe} and Saveria Minucci",
year = "2005",
month = "1",
language = "English",
volume = "4",
pages = "67--69",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Leukemia-associated fusion proteins

T2 - Multiple mechanisms of action to drive cell transformation

AU - Insinga, Alessandra

AU - Pelicci, Pier Giuseppe

AU - Minucci, Saveria

PY - 2005/1

Y1 - 2005/1

N2 - Leukemic cells are defined by two main biological features: arrest of differentiation at a specific stage compatible with continued proliferation, and enhanced resistance to stress. Recent work shows that the leukemia-associated fusion protein PML-RAR can mediate both biological effects targeting independent pathways, through a unifying mechanism. Differentiation block is achieved through transcriptional silencing of genes physiologically regulated by RAR, which are involved in hematopoietic differentiation. In contrast, enhanced resistance to stress is due to the capacity of the fusion protein to cause degradation of the tumor suppressor p53, thus explaining the puzzling observation that mutations of p53 are remarkably rare in acute myeloid leukemias (AMLs). Interestingly, this latter phenomenon depends on expression of wild-type PML, acting as a molecular bridge between p53 and the fusion protein. Strikingly, both effects require a unifying molecular mechanism: aberrant recruitment of histone deacetylases (HDACs). Therefore, the study of this form of leukemia appears also of interest for a better understanding of the action of HDAC inhibitors, potential antitumor drugs that are at the early stages of clinical studies.

AB - Leukemic cells are defined by two main biological features: arrest of differentiation at a specific stage compatible with continued proliferation, and enhanced resistance to stress. Recent work shows that the leukemia-associated fusion protein PML-RAR can mediate both biological effects targeting independent pathways, through a unifying mechanism. Differentiation block is achieved through transcriptional silencing of genes physiologically regulated by RAR, which are involved in hematopoietic differentiation. In contrast, enhanced resistance to stress is due to the capacity of the fusion protein to cause degradation of the tumor suppressor p53, thus explaining the puzzling observation that mutations of p53 are remarkably rare in acute myeloid leukemias (AMLs). Interestingly, this latter phenomenon depends on expression of wild-type PML, acting as a molecular bridge between p53 and the fusion protein. Strikingly, both effects require a unifying molecular mechanism: aberrant recruitment of histone deacetylases (HDACs). Therefore, the study of this form of leukemia appears also of interest for a better understanding of the action of HDAC inhibitors, potential antitumor drugs that are at the early stages of clinical studies.

KW - Apoptosis

KW - Leukemia

KW - Mouse model

KW - Oncogenic fusion protein

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=17444372641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444372641&partnerID=8YFLogxK

M3 - Article

C2 - 15611639

AN - SCOPUS:17444372641

VL - 4

SP - 67

EP - 69

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 1

ER -